Shattuck Labs Inc
STTK
View Detailed Chart
3.140USD
-0.010-0.32%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
198.30MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-0.32%
5 Days
+2.61%
1 Month
+54.68%
6 Months
+228.14%
Year to Date
+159.50%
1 Year
+173.04%
View Detailed Chart
TradingKey Stock Score of Shattuck Labs Inc
Currency: USD Updated: 2025-12-22Key Insights
Shattuck Labs Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 80/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 4.00.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Shattuck Labs Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
6
analysts
Buy
Current Rating
4.000
Target Price
+32.89%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Shattuck Labs Inc Highlights
StrengthsRisks
Shattuck Labs, Inc. is a biotechnology company. The Company is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The Company is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. It is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 777.45% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 5.72M.
Undervalued
The company’s latest PE is -3.17, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 32.72M shares, decreasing 3.65% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 34.30K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 6.26.
Shattuck Labs Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Shattuck Labs Inc Info
Shattuck Labs, Inc. is a biotechnology company. The Company is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The Company is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. It is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.
Ticker SymbolSTTK
CompanyShattuck Labs Inc
CEOSchreiber (Taylor)
Websitehttps://www.shattucklabs.com/
FAQs
What is the current price of Shattuck Labs Inc (STTK)?
The current price of Shattuck Labs Inc (STTK) is 3.140.
What is the symbol of Shattuck Labs Inc?
The ticker symbol of Shattuck Labs Inc is STTK.
What is the 52-week high of Shattuck Labs Inc?
The 52-week high of Shattuck Labs Inc is 3.380.
What is the 52-week low of Shattuck Labs Inc?
The 52-week low of Shattuck Labs Inc is 0.692.
What is the market capitalization of Shattuck Labs Inc?
The market capitalization of Shattuck Labs Inc is 198.30M.
What is the net income of Shattuck Labs Inc?
The net income of Shattuck Labs Inc is -75.41M.
Is Shattuck Labs Inc (STTK) currently rated as Buy, Hold, or Sell?
According to analysts, Shattuck Labs Inc (STTK) has an overall rating of Buy, with a price target of 4.000.
What is the Earnings Per Share (EPS TTM) of Shattuck Labs Inc (STTK)?
The Earnings Per Share (EPS TTM) of Shattuck Labs Inc (STTK) is -0.991.
Related Instruments
+0.44%
+0.43%
+0.45%
+0.21%
+0.60%
+3.60%
+1.22%
+0.04%
-0.10%
+0.10%
-0.31%
+0.90%
+0.82%
-0.25%
-0.02%
+0.71%
+1.48%
0.00%
+1.25%
+1.87%
